» Articles » PMID: 36294924

Heat Shock Protein 70 and 90 Family in Prostate Cancer

Overview
Journal Life (Basel)
Specialty Biology
Date 2022 Oct 27
PMID 36294924
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) is the second most frequent cancer that affects aging men worldwide. However, its exact pathogenesis has not been fully elucidated. The heat shock protein (HSP) family has cell-protective properties that may promote tumor growth and protect cancer cells from death. On a cellular level, HSP molecules have a strong relationship with multiple important biological processes, such as cell differentiation, epithelial-mesenchymal transition (EMT), and fibrosis. Because of the facilitation of HSP family molecules on tumorigenesis, a number of agents and inhibitors are being developed with potent antitumor effects whose target site is the critical structure of HSP molecules. Among all target molecules, HSP70 family and HSP90 are two groups that have been well studied, and therefore, the development of their inhibitors makes great progress. Only a small number of agents, however, have been clinically tested in recruited patients. As a result, more clinical studies are warranted for the establishment of the relationship between the HSP70 family, alongside the HSP90 molecule, and prostate cancer treatment.

Citing Articles

Spatial Genomics Identifies Heat Shock Proteins as Key Molecular Changes Associated to Adipose Periprostatic Space Invasion in Prostate Cancer.

Cussenot O, Poupel L, Mousset C, Lavergne J, Bruyere F, Fontaine A Cancers (Basel). 2025; 17(1.

PMID: 39796635 PMC: 11718861. DOI: 10.3390/cancers17010002.


Investigating the role of HSP90 in cancer cell phenotypic plasticity.

Sollars V, Chapman A, Liang N, Myers S J Breast Cancer Res. 2024; 4(1):5-10.

PMID: 39363892 PMC: 11448696. DOI: 10.46439/breastcancer.4.021.


Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.

Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).

PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.


Unveiling the Molecular Landscape of Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies.

Hwang K, Yun J, Kim H Int J Mol Sci. 2023; 24(21).

PMID: 37958805 PMC: 10650174. DOI: 10.3390/ijms242115823.


Hsp70-A Universal Biomarker for Predicting Therapeutic Failure in Human Female Cancers and a Target for CTC Isolation in Advanced Cancers.

Xanthopoulos A, Samt A, Guder C, Taylor N, Roberts E, Herf H Biomedicines. 2023; 11(8).

PMID: 37626772 PMC: 10452093. DOI: 10.3390/biomedicines11082276.


References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Allan R, Mok D, Ward B, Ratajczak T . Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem. 2006; 281(11):7161-71. DOI: 10.1074/jbc.M512406200. View

3.
Ono K, Sogawa C, Kawai H, Tran M, Taha E, Lu Y . Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer. J Extracell Vesicles. 2020; 9(1):1769373. PMC: 7580842. DOI: 10.1080/20013078.2020.1769373. View

4.
Woolf C . An investigation of the familial aspects of carcinoma of the prostate. Cancer. 1960; 13:739-44. DOI: 10.1002/1097-0142(196007/08)13:4<739::aid-cncr2820130414>3.0.co;2-e. View

5.
Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L . The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349(3):215-24. DOI: 10.1056/NEJMoa030660. View